{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006794","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.284718+00:00","generated_at":"2026-06-08T13:25:53.989004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%","bullets":["Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.","GAAP net loss $1.2M ($0.03/share); adjusted EPS $0.01; adjusted EBITDA $2.2M (8.9% margin).","Operating cash flow $4.4M; debt reduced $2.8M in Q3, total debt $38.7M.","Updated FY2023 guidance: revenue approx flat YoY, gross margin ~60%, adjusted EBITDA margin 13%-14%.","Asia headwinds and $1.3M revenue impact from discontinued products; North America revenue grew."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006794","json":"https://secwatch.observer/filing/0001171843-23-006794.json","markdown":"https://secwatch.observer/filing/0001171843-23-006794.md","text":"https://secwatch.observer/filing/0001171843-23-006794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/f8k_110323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:25:53.989004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33897daef91efebdbccd53acf10a1823efe80547","claim":"HARVARD BIOSCIENCE INC reported the third quarter ended September 30, 2023 results: revenue $25.4 million, net income ($1.2) million, EPS $(0.03).","evidence_excerpt":"a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2023 Financial Results · Q3 Revenues of $25.4 million · Q3 Gross Margin of 58.1% · Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million · Continued strong operating cash flow drove debt reduction of $8.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$25.4 million"},{"label":"Net income","value":"($1.2) million"},{"label":"EPS","value":"$(0.03)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5a117d511888f36e7ca3ff00978417c82ac8fe73","claim":"HARVARD BIOSCIENCE INC updated its fiscal 2023 guidance (reaffirmed).","evidence_excerpt":"we now expect our fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5 percentage point headwind from discontinued products. For the year 2023, we continue to expect gross margins of approximately 60%. We now expect adjusted EBITDA margins in the 13% to 14% range.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a32df3f73ebecdc14b5a4a7d06937eae4f436ced","claim":"HARVARD BIOSCIENCE INC reported the nine months ended September 30, 2023 results: revenue $84.1 million, net income ($1.6) million, EPS $(0.04).","evidence_excerpt":"debt was reduced by $3.8 million during the third quarter of 2023. Nine Months ended September 30, 2023 Highlights For the nine months ended September 30, 2023, revenues were $84.1 million, compared to $84.9 million in the same period a year ago. Revenues for the nine months ended September 30, 2023 include a net reduction of $4.1 million from discontinued products","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Revenue","value":"$84.1 million"},{"label":"Net income","value":"($1.6) million"},{"label":"EPS","value":"$(0.04)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}